Precision Advance aims to improve patient access to cell and gene therapy


October 14, 2021 -- Improving patient access to cell and gene therapy treatments is the goal of Precision Advance, an initiative of Precision Medicine Group. Precision Advance provides a set of interconnected services and personnel designed to help bring new therapies to market.

Precision Medicine Group made a major investment in Precision Advance earlier in 2021 through the acquisition of Project Farma, a bioengineering services firm that supports life sciences researchers. Project Farma specializes in planning and implementing complex biomanufacturing strategies, and has led the construction of more than a dozen manufacturing facilities.

Project Farma is now part of Precision for Medicine, Precision Medicine Group's research and development services arm, as well as Precision Advance, the company's dedicated cell and gene therapy business.

Learn more about Precision Advance, Project Farma, and Precision Medicine Group in this video.

Video loading ...

Precision Medicine acquires Project Farma
Precision Medicine has acquired Project Farma, a bioengineering services firm.

Copyright © 2021 scienceboard.net


Conferences
Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter